Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population ...

Serum Institute and DNDi sign MoU to develop and scale a dengue monoclonal antibody vaccine with Phase 3 trials in India, ...

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced ...

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, ...

Kennedy, a longtime anti-vaccine activist who had criticized the panel of experts, said he would pick the committee's new members.

Africa is grappling with a worsening mpox crisis, with a critical shortfall of vaccine doses threatening to derail ...

The Bavarian town of Oberstdorf will be Germany's bidder for the 2031 Nordic skiing world championships, the German Ski ...

Critical voices on unfairly high mpox and other vaccine prices open the debate on the ‘right price’ to be paid to private vaccine suppliers. We apply compound real options analysis as a more ...

Bavarian Nordic reported a robust start to 2025 with a 62% year-over-year increase in revenue for the first quarter, reaching 1,347 million Danish krona. Despite the absence of specific earnings f ...

The United States Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) has recommended Bavarian Nordic’s recombinant vaccine for the prevention of ...

Looking ahead to the rest of the year, Bavarian Nordic aims to grow earnings some 26% to 30% over that same span. As for what could be next in the company’s travel health portfolio, Bavarian ...

Bavarian Nordic reported a strong financial performance in Q4 2024, with significant revenue growth and a solid EBITDA margin. The company’s stock price rose by 2.32% following the earnings ...